A combination of the CXCR4 antagonist X4P‐001 in combination with Pembrolizumab reactivating CD8 TIL (Emancipator, 2020) demonstrated a clinical response in patients with advanced melanoma (phase 1b trial, NCT02823405). This evidence concerns the gene CXCR4 and melanoma.